TC BioPharm (Holdings) plc financial data

Symbol
TCBPY, TCBWF on OTC
Location
Holytown, United Kingdom
Fiscal year end
31 December
Latest financial report
20-F - Q4 2024 - 09 May 2025

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1,991,478,441 shares
Common Stock, Shares, Outstanding 2,550,807,451 shares 12301%
Common Stock, Value, Issued £255,082 GBP 12301%
Weighted Average Number of Shares Outstanding, Basic 30,138,602 shares 1369%
Weighted Average Number of Shares Outstanding, Diluted 30,138,602 shares 1369%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense £1,298,942 GBP -33%
General and Administrative Expense £2,142,714 GBP -4%
Operating Income (Loss) £3,441,656 GBP 17%
Nonoperating Income (Expense) £9,060 GBP -100%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest £3,432,596 GBP -232%
Income Tax Expense (Benefit) £110,742 GBP 72%
Net Income (Loss) Attributable to Parent £3,321,854 GBP -423%
Earnings Per Share, Basic -0.11 GBP/shares 65%
Earnings Per Share, Diluted -0.11 GBP/shares 65%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $1,500,000 USD
Assets, Current £5,774,651 GBP 1.3%
Property, Plant and Equipment, Net £954,808 GBP -25%
Operating Lease, Right-of-Use Asset £1,132,816 GBP -16%
Intangible Assets, Net (Excluding Goodwill) £466,262 GBP -24%
Assets £8,328,537 GBP -6.8%
Accounts Payable, Current £942,267 GBP
Accrued Liabilities, Current £1,011,943 GBP -18%
Liabilities, Current £4,147,895 GBP -13%
Operating Lease, Liability, Noncurrent £1,171,019 GBP -22%
Liabilities £5,318,914 GBP -15%
Retained Earnings (Accumulated Deficit) £52,559,029 GBP -30%
Stockholders' Equity Attributable to Parent $3,800,000 USD
Liabilities and Equity £8,328,537 GBP -6.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities £2,408,593 GBP 17%
Net Cash Provided by (Used in) Financing Activities £932,557 GBP -76%
Net Cash Provided by (Used in) Investing Activities £5,618 GBP 96%
Common Stock, Shares Authorized 2,550,807,451 shares 12301%
Common Stock, Shares, Issued 2,550,807,451 shares 12301%
Common Stock, Par or Stated Value Per Share 0 GBP/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect £1,481,654 GBP -265%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents £1,215,640 GBP -51%
Deferred Tax Assets, Valuation Allowance £6,272,590 GBP 41%
Deferred Tax Assets, Gross £6,272,590 GBP 41%
Operating Lease, Liability £1,499,483 GBP -17%
Depreciation £114,745 GBP -32%
Property, Plant and Equipment, Gross £5,495,777 GBP 1.2%
Operating Lease, Liability, Current £328,464 GBP 7.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two £447,015 GBP 0%
Lessee, Operating Lease, Liability, to be Paid, Year One £447,015 GBP 0%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, to be Paid, Year Three £447,015 GBP 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four £447,015 GBP 0%
Operating Lease, Payments £111,754 GBP 0%
Additional Paid in Capital £54,916,172 GBP 29%
Amortization of Intangible Assets £12,276 GBP 3.9%